Patents by Inventor Igor Mochalkin

Igor Mochalkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 inhibitors and uses thereof
    Patent number: 12084438
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 10, 2024
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Carboxamide-pyrimidine derivatives as SHP2 antagonists
    Patent number: 11696916
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: July 11, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Igor Mochalkin, Theresa Johnson, Nina Linde, Doreen Musch, Deepak Kumar
  • CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20220362244
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: April 30, 2021
    Publication date: November 17, 2022
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Igor MOCHALKIN, Theresa JOHNSON, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20220340577
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 15, 2020
    Publication date: October 27, 2022
    Inventors: Andrew BAYLY, Matthew BLEICH, Jean-Damien CHARRIER, James DODD, Steven DURRANT, Meredith Suzanne ENO, Gorka ETXEBARRIA I JARDI, Simon EVERITT, Damien FRAYSSE, Shazia KELLY, Ronald KNEGTEL, Igor MOCHALKIN, Michael MORTIMORE, Kiri NORTH, Filippos PORICHIS, Robert PULLIN, Alistair RUTHERFORD, Pierre-Henri STORCK, Heather Clare TWIN
  • Carboxamide-pyrimidine derivatives as SHP2 antagonists
    Patent number: 11033547
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 15, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-LeBrun, Roch Boivin, Igor Mochalkin, Theresa Johnson, Nina Linde, Doreen Musch, Deepak Kumar
  • GCN2 inhibitors and uses thereof
    Patent number: 10988477
    Abstract: The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: April 27, 2021
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20210040083
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: February 11, 2021
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 inhibitors and uses thereof
    Patent number: 10793563
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 6, 2020
    Assignees: MERCK PATENT GMBH, VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20200281926
    Abstract: The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: March 9, 2020
    Publication date: September 10, 2020
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Igor MOCHALKIN, Theresa JOHNSON, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233425
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10329270
    Abstract: The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: June 25, 2019
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Constantin Neagu, Igor Mochalkin, Lesley Liu-Bujalski, Reinaldo Jones, Devon Tate, Theresa L. Johnson, Anna Gardberg
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 10080750
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20180243324
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 10005784
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 9738648
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 22, 2017
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20170226113
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazene compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Inventors: Lesley LIU-BUJALSKI, Ngan NGUYEN, Hui QIU, Reinaldo JONES, Igor MOCHALKIN, Richard D. CALDWELL